|
38 Companies |
|
27 Products |
|
27 Products |
|
30 Mechanisms of Action |
|
3 Trials |
|
274 News |
|
| 123456» |
- | TuNEX (etanercept biosimilar) / TTY Biopharm, Mycenax
Enrollment change, Trial termination, Trial primary completion date: A Multicentre Study to Evaluate the Efficacy and Safety of ENIA11 in Patients With Ankylosing Spondylitis (clinicaltrials.gov) - Mar 12, 2019
P3, N=10, Terminated, Sponsor: Mycenax Biotech Inc.
N=90 --> 10 | Recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Jan 2018; Sponsor's decision
- ||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial completion: HARIR: Tracking Biologics Along the Silk Road (clinicaltrials.gov) - Jan 10, 2019
P=N/A, N=140, Completed, Sponsor: Janssen Pharmaceutica N.V., Belgium
N=90 --> 10 | Recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Jan 2018; Sponsor's decision Active, not recruiting --> Completed
- | Trial completion: A Clinimetric Test of Spinal Sensors in Measuring Spinal Mobility in Axial Spondyloarthritis (clinicaltrials.gov) - Jan 2, 2019
P=N/A, N=40, Completed, Sponsor: Dr Philip Gardiner
Active, not recruiting --> Completed Recruiting --> Completed
- ||| Trial completion, Phase classification, Enrollment change: Augment® Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions (clinicaltrials.gov) - Dec 5, 2018
P=N/A, N=299, Completed, Sponsor: BioMimetic Therapeutics
Recruiting --> Completed Active, not recruiting --> Completed | Phase classification: P3 --> PN/A | N=201 --> 299
- | Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial completion date, Trial primary completion date: HARIR: Tracking Biologics Along the Silk Road (clinicaltrials.gov) - Nov 2, 2018
P=N/A, N=140, Active, not recruiting, Sponsor: Janssen Pharmaceutica N.V., Belgium
Active, not recruiting --> Completed | Phase classification: P3 --> PN/A | N=201 --> 299 Trial completion date: Dec 2019 --> Dec 2018 | Trial primary completion date: Dec 2019 --> Dec 2018
- | Cosentyx (secukinumab) / Novartis
Trial primary completion date: MEASURE 3: 16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients (clinicaltrials.gov) - Oct 11, 2018
P3, N=226, Completed, Sponsor: Novartis Pharmaceuticals
Trial completion date: Dec 2019 --> Dec 2018 | Trial primary completion date: Dec 2019 --> Dec 2018 Trial primary completion date: Aug 2015 --> Dec 2017
- | Jyseleca (filgotinib) / Galapagos, Gilead
Trial completion: TORTUGA: A Study to Assess Efficacy and Safety of Filgotinib in Ankylosing Spondylitis (clinicaltrials.gov) - Aug 13, 2018
P2, N=116, Completed, Sponsor: Galapagos NV
Trial primary completion date: Aug 2015 --> Dec 2017 Active, not recruiting --> Completed
- || Inflectra (infliximab biosimilar IV) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer
Trial primary completion date: An Observational Study to Evaluate Safety and Efficacy of Remsima™ in Patients With Ankylosing Spondylitis (clinicaltrials.gov) - Jul 24, 2018
P=N/A, N=1000, Recruiting, Sponsor: Celltrion
Active, not recruiting --> Completed Trial primary completion date: Dec 2019 --> Jun 2020
- | Enbrel (etanercept) / Pfizer, Amgen
Trial completion: Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis (clinicaltrials.gov) - Jun 18, 2018
P4, N=150, Completed, Sponsor: Sun Yat-sen University
Trial primary completion date: Dec 2019 --> Jun 2020 Active, not recruiting --> Completed
- ||||||| Cosentyx (secukinumab) / Novartis
Trial completion: MEASURE 3: 16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients (clinicaltrials.gov) - Jun 7, 2018
P3, N=226, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Sulinno (adalimumab biosimilar) / Innovent Biologics
Trial completion, Trial completion date: Efficacy and Safety of IBI303 in Adult Patients With Active Ankylosing Spondylitis (clinicaltrials.gov) - Jun 4, 2018
P3, N=438, Completed, Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Active, not recruiting --> Completed Not yet recruiting --> Completed | Trial completion date: Dec 2018 --> Mar 2018
- ||||||| Cosentyx (secukinumab) / Novartis
Trial completion, Trial primary completion date: MEASURE4: 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis (clinicaltrials.gov) - Apr 18, 2018
P3, N=350, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Completed | Trial completion date: Dec 2018 --> Mar 2018 Active, not recruiting --> Completed | Trial primary completion date: Feb 2016 --> Jan 2018
- || Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Enrollment closed: HARIR: Tracking Biologics Along the Silk Road (clinicaltrials.gov) - Apr 17, 2018
P=N/A, N=140, Active, not recruiting, Sponsor: Janssen Pharmaceutica N.V., Belgium
Active, not recruiting --> Completed | Trial primary completion date: Feb 2016 --> Jan 2018 Recruiting --> Active, not recruiting
- ||| Jyseleca (filgotinib) / Galapagos, Gilead
Enrollment closed: TORTUGA: A Study to Assess Efficacy and Safety of Filgotinib in Ankylosing Spondylitis (clinicaltrials.gov) - Mar 12, 2018
P2, N=116, Active, not recruiting, Sponsor: Galapagos NV
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||||| BCD-055 (infliximab biosimilar) / Biocad
Trial completion, Trial completion date, Trial primary completion date: Comparative Clinical Trial to Evaluate Efficacy and Safety of BCD-055 and Remicade® in Patients With Ankylosing Spondylitis (clinicaltrials.gov) - Feb 23, 2018
P3, N=199, Completed, Sponsor: Biocad
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: May 2018 --> May 2017 | Trial completion date: May 2018 --> Jul 2017
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion, Enrollment change: Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation) (clinicaltrials.gov) - Jan 26, 2018
P=N/A, N=401, Completed, Sponsor: AbbVie
Active, not recruiting --> Completed | Trial primary completion date: May 2018 --> May 2017 | Trial completion date: May 2018 --> Jul 2017 Active, not recruiting --> Completed | N=100 --> 401
- Enrollment change, Trial termination, Trial primary completion date: SI Joint Fusion and Decortication Using the SImmetry System (clinicaltrials.gov) - Dec 22, 2017
P=N/A, N=17, Terminated, Sponsor: Zyga Technology, Inc.
Active, not recruiting --> Completed | N=100 --> 401 N=25 --> 17 | Recruiting --> Terminated | Trial primary completion date: Aug 2018 --> Dec 2017; No additional enrollment
- |||| Cosentyx (secukinumab) / Novartis
Trial primary completion date: MEASURE4: 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis (clinicaltrials.gov) - Nov 30, 2017
P3, N=350, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=25 --> 17 | Recruiting --> Terminated | Trial primary completion date: Aug 2018 --> Dec 2017; No additional enrollment Trial primary completion date: Jan 2018 --> Feb 2016
- || Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Enrollment change: HARIR: Tracking Biologics Along the Silk Road (clinicaltrials.gov) - Nov 6, 2017
P=N/A, N=150, Recruiting, Sponsor: Janssen Pharmaceutica N.V., Belgium
Trial primary completion date: Jan 2018 --> Feb 2016 N=338 --> 150
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Enrollment change, Trial termination, Trial primary completion date: RECOVERY: An Observational Study of Infliximab in Participants Suffering From Ankylosing Spondylitis With Hip Involvement (clinicaltrials.gov) - Nov 1, 2017
P=N/A, N=76, Terminated, Sponsor: Janssen Research & Development, LLC
N=338 --> 150 N=220 --> 76 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2017 --> May 2017; The project was stopped by 31-May-2017 because of internal owner decision from out of balance enrollment from two groups.
- | Trial completion: Effect of Biological Disease Modifying Anti Rheumatic Drug (bDMARD) Treatment on Spinal Fracture Incidence in Patients With Ankylosing Spondylitis (AS) (clinicaltrials.gov) - Oct 30, 2017
P=N/A, N=9858, Completed, Sponsor: Uppsala University
N=220 --> 76 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2017 --> May 2017; The project was stopped by 31-May-2017 because of internal owner decision from out of balance enrollment from two groups. Active, not recruiting --> Completed
- | Stelara (ustekinumab) / J&J
Trial termination: An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial Spondyloarthritis (clinicaltrials.gov) - Oct 25, 2017
P3, N=356, Terminated, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Terminated; This study was stopped because ustekinumab did not achieve key endpoints in a related study. The safety profile was consistent with past ustekinumab studies.
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion, Enrollment change, Adherence: Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice (clinicaltrials.gov) - Oct 19, 2017
P=N/A, N=96, Completed, Sponsor: AbbVie
The safety profile was consistent with past ustekinumab studies. Active, not recruiting --> Completed | N=140 --> 96
- ||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial completion, Review, Trial primary completion date: Analysis of Birth Outcomes of Swedish, Danish and Finnish Women Exposed to Remicade With Inflammatory Bowel Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Psoriasis (clinicaltrials.gov) - Sep 6, 2017
P=N/A, N=370, Completed, Sponsor: Janssen Biotech, Inc.
Active, not recruiting --> Completed | N=140 --> 96 Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Sep 2016
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: AS PMOS: Observe the Frequency of Extra-Axial Symptoms in Korean Ankylosing Spondylitis (AS) Patients (clinicaltrials.gov) - Aug 15, 2017
P=N/A, N=201, Completed, Sponsor: AbbVie
Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Sep 2016 Active, not recruiting --> Completed
- |||| Stelara (ustekinumab) / J&J
Trial primary completion date: An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial Spondyloarthritis (clinicaltrials.gov) - Aug 14, 2017
P3, N=356, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Trial primary completion date: Jan 2018 --> Sep 2017
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion, Observational data: SPACTIVE: Study in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) Patients to Evaluate Work Productivity Before and After the Start of Adalimumab Therapy in Daily Practice in Belgium (clinicaltrials.gov) - Jul 11, 2017
P=N/A, N=183, Completed, Sponsor: AbbVie
Trial primary completion date: Jan 2018 --> Sep 2017 Active, not recruiting --> Completed
- ||||| Stelara (ustekinumab) / J&J
Enrollment closed: An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial Spondyloarthritis (clinicaltrials.gov) - Jun 16, 2017
P3, N=356, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Enrollment closed: RECOVERY: An Observational Study of Infliximab in Participants Suffering From Ankylosing Spondylitis With Hip Involvement (clinicaltrials.gov) - Jun 14, 2017
P=N/A, N=220, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || Inflectra (infliximab biosimilar IV) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer
Trial primary completion date: An Observational Study to Evaluate Safety and Efficacy of Remsima™ in Patients With Ankylosing Spondylitis (clinicaltrials.gov) - Jun 14, 2017
P=N/A, N=1000, Recruiting, Sponsor: Celltrion
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2017 --> Dec 2019
- ||| Enbrel (etanercept) / Pfizer, Amgen
Trial completion, Enrollment change: REACH AS: Defining Remission With Etanercept in AS in Real Life Clinical Practice (clinicaltrials.gov) - Jun 7, 2017
P=N/A, N=76, Completed, Sponsor: Pfizer
Trial primary completion date: Sep 2017 --> Dec 2019 Recruiting --> Completed | N=140 --> 76
- | New trial: A Clinimetric Test of Spinal Sensors in Measuring Spinal Mobility in Axial Spondyloarthritis (clinicaltrials.gov) - May 19, 2017
P=N/A, N=40, Recruiting, Sponsor: Dr Philip Gardiner
- | Zostavax (zoster vaccine live) / Merck (MSD)
Trial primary completion date: Safety and Effectiveness Study of the Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE) (clinicaltrials.gov) - May 4, 2017
P2, N=125, Active, not recruiting, Sponsor: University of Alabama at Birmingham
Recruiting --> Completed | N=140 --> 76 Trial primary completion date: Apr 2017 --> Feb 2018
- |||||| TuNEX (etanercept biosimilar) / TTY Biopharm, Mycenax
Enrollment open, Trial initiation date, Trial primary completion date: A Multicentre Study to Evaluate the Efficacy and Safety of ENIA11 in Patients With Ankylosing Spondylitis (clinicaltrials.gov) - Apr 28, 2017
P3, N=90, Recruiting, Sponsor: TSH Biopharm Corporation Limited
Trial primary completion date: Apr 2017 --> Feb 2018 Not yet recruiting --> Recruiting | Initiation date: Mar 2016 --> Sep 2016 | Trial primary completion date: Dec 2017 --> Dec 2018
- | Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Phase classification: HARIR: Tracking Biologics Along the Silk Road (clinicaltrials.gov) - Apr 21, 2017
P=N/A, N=338, Recruiting, Sponsor: Janssen Pharmaceutica N.V., Belgium
Not yet recruiting --> Recruiting | Initiation date: Mar 2016 --> Sep 2016 | Trial primary completion date: Dec 2017 --> Dec 2018 Phase classification: P4 --> P=N/A
- ||||| Jyseleca (filgotinib) / Galapagos, Gilead
New P2 trial: TORTUGA: A Study to Assess Efficacy and Safety of Filgotinib in Ankylosing Spondylitis (clinicaltrials.gov) - Apr 17, 2017
P2, N=100, Recruiting, Sponsor: Galapagos NV
- ||||| BCD-055 (infliximab biosimilar) / Biocad
Enrollment closed: Comparative Clinical Trial to Evaluate Efficacy and Safety of BCD-055 and Remicade® in Patients With Ankylosing Spondylitis (clinicaltrials.gov) - Mar 28, 2017
P3, N=198, Active, not recruiting, Sponsor: Biocad
Phase classification: P4 --> P=N/A Recruiting --> Active, not recruiting
- | entecavir / Generic mfg.
Enrollment change: Study of Anti-Viral Prophylaxis for HBsAg(+) or HBcAb(+)/HBsAb(-) Patients Starting Anti-TNFα (clinicaltrials.gov) - Mar 6, 2017
P3, N=43, Terminated, Sponsor: Seoul National University Hospital
Recruiting --> Active, not recruiting N=128 --> 43
- | Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Phase classification, Review: Analysis of Birth Outcomes of Swedish, Danish and Finnish Women Exposed to Remicade With Inflammatory Bowel Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Psoriasis (clinicaltrials.gov) - Mar 3, 2017
P=N/A, N=370, Active, not recruiting, Sponsor: Janssen Biotech, Inc.
N=128 --> 43 Phase classification: P4 --> P=N/A
- || Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Phase classification, Trial primary completion date: RECOVERY: An Observational Study of Infliximab in Participants Suffering From Ankylosing Spondylitis With Hip Involvement (clinicaltrials.gov) - Feb 15, 2017
P=N/A, N=220, Recruiting, Sponsor: Janssen Research & Development, LLC
Phase classification: P4 --> P=N/A Phase classification: P4 --> P=N/A | Trial primary completion date: Dec 2016 --> Dec 2017
- Zostavax (zoster vaccine live) / Merck (MSD)
Trial primary completion date: Safety and Effectiveness Study of the Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE) (clinicaltrials.gov) - Jan 23, 2017
P2, N=125, Active, not recruiting, Sponsor: University of Alabama at Birmingham
Phase classification: P4 --> P=N/A | Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Dec 2016 --> Apr 2017
- ||||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
New P4 trial: HARIR: Tracking Biologics Along the Silk Road (clinicaltrials.gov) - Dec 30, 2016
P4, N=338, Recruiting, Sponsor: Janssen Pharmaceutica N.V., Belgium
- Zostavax (zoster vaccine live) / Merck (MSD)
Enrollment closed, Trial primary completion date: Safety and Effectiveness Study of the Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE) (clinicaltrials.gov) - Dec 27, 2016
P2, N=125, Active, not recruiting, Sponsor: University of Alabama at Birmingham
Trial primary completion date: Dec 2016 --> Apr 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Dec 2016
- ||||||| Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial completion: A Study of Golimumab in Participants With Active Ankylosing Spondylitis (clinicaltrials.gov) - Dec 1, 2016
P3, N=208, Completed, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Dec 2016 Active, not recruiting --> Completed
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment closed, Adherence: Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice (clinicaltrials.gov) - Nov 30, 2016
P=N/A, N=140, Active, not recruiting, Sponsor: AbbVie
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial completion, Biopsy: Biopsychosocial Exploration of Pain Profiles in Inflammatory and Chronic Non-specific Axial Low Back Pain (clinicaltrials.gov) - Oct 21, 2016
P=N/A, N=58, Completed, Sponsor: University of Dublin, Trinity College
Recruiting --> Active, not recruiting Recruiting --> Completed
- Enbrel (etanercept) / Pfizer, Amgen
New P4 trial: Relapse of Ankylosing Spondylitis Patients Withdrawal Etanercept After Clinical Remission: a Following-up Study (clinicaltrials.gov) - Sep 27, 2016
P4, N=35, Completed, Sponsor: Sun Yat-sen University
- | Trial completion: CT Follow-Up of the SImmetry Sacroiliac Joint Fusion System (clinicaltrials.gov) - Sep 13, 2016
P=N/A, N=19, Completed, Sponsor: Zyga Technology, Inc.
Recruiting --> Completed Enrolling by invitation --> Completed
- || Sulinno (adalimumab biosimilar) / Innovent Biologics
New P3 trial: Efficacy and Safety of IBI303 in Adult Patients With Active Ankylosing Spondylitis (clinicaltrials.gov) - Sep 8, 2016
P3, N=400, Not yet recruiting, Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
- New trial: C.O.R.P.U.S.: Observational Cohort of Adult and Child Inflammatory Arthritis in France (clinicaltrials.gov) - Sep 1, 2016
P=N/A, N=5400, Completed, Sponsor: Central Hospital, Nancy, France